What compounded semaglutide is, how it differs from the registered product, which risks matter most, and what to ask your doctor and pharmacy before you choose.

If you've tried to refill a semaglutide prescription lately, you've probably hit one of two walls. The registered pen costs more than you can comfortably pay, or it's simply out of stock. That gap is why so many people now ask their doctor or a compounding pharmacy about compounded semaglutide, the version mixed in small batches or by hand from a bulk active ingredient. The question is fair. The answer is less simple than 'cheaper, same thing.'

This post doesn't repeat our earlier coverage of counterfeit pens. Here we look at the legal and technical gap between a compounded product and the registered one, and at what that gap means for your dose. We aren't saying compounded semaglutide is always bad. Compounding has a legitimate place for specific patients. It does call for extra care, and that's what this guide focuses on.

Why the shortage changed the conversation

In the United States, the FDA removed semaglutide from its drug shortage list in early 2025. While the shortage lasted, compounders were allowed to make versions of the drug. Once the agency's transition periods ended, copying an approved drug became much harder to justify. Agency policy can change, so check the FDA's shortage and compounding pages for the current status.

In Brazil, the term is semaglutida manipulada, and the rules come from ANVISA. The agency sets good practice standards for compounding and issues alerts on GLP-1 products, and those notices get updated over time. What's allowed on the day you read this may differ from what we describe here. Check ANVISA's medicines pages before you decide anything about semaglutida manipulada ANVISA regras.

What compounded semaglutide actually is

A compounding pharmacy prepares a medicine for a specific patient, usually under an individual prescription. It starts from an active pharmaceutical ingredient, or API (in Portuguese, IFA, insumo farmacêutico ativo). The API is the raw substance that produces the drug's effect. Its origin matters because the manufacturer, purity, and salt form of that powder all shape what ends up in the syringe. Two products labeled 'semaglutide' can come from different suppliers with very different quality controls.

ANVISA's good practice rules for compounding pharmacies require control over raw materials, equipment, preparation steps, and labeling. Those controls matter. They don't turn a compounded product into a registered one, though. Registration means the agency reviewed clinical evidence and approved a specific composition and presentation. Compounding doesn't come with that review.

The United States splits things along similar lines. Under sections 503A and 503B of the federal food law, 503A pharmacies compound for individual prescriptions, while 503B outsourcing facilities produce larger batches. The FDA's position is that compounders shouldn't make drugs that are essentially copies of approved products, unless a prescriber documents a clinical reason for that specific patient. A patient who reacts to an ingredient in the registered pen is a legitimate example. Using compounded semaglutide as a routine, cheaper stand-in is the pattern regulators worry about.

How it differs from the registered product (semaglutida manipulada vs original)

Approval

The registered product went through clinical trials that tested efficacy and safety. Programs such as SUSTAIN, which studied type 2 diabetes, and STEP, which studied weight management, helped shape the dosing and the safety information in the registered label. A compounded version doesn't go through that evaluation, so nobody has tested that specific preparation in those trials.

Consistency

Concentration, purity, and the real volume of each dose can vary between batches and between pharmacies. Two patients can receive vials with identical labels and different amounts of active ingredient. This is the most fragile point of the comparison, and it's the reason to ask for batch testing.

Presentation

The registered pen delivers pre-set doses. Compounded versions often come as vials or syringes, where you measure the dose in milliliters or in units on a syringe. Each conversion step is another chance for a calculation error.

Chemical form

Some compounded products use salt forms or excipients that differ from the registered formula. We're not claiming those are equivalent, and we're not claiming they're unsafe. The registered product has a defined composition written in its bula, so you can compare it with the label of any compounded option. Ask the pharmacy exactly which form it uses.

The real risks, without the drama

Compounded semaglutide risks: dosing errors

Dosing errors deserve the most attention. Milligrams, milliliters, and units measure different things, and mixing them up can produce a dose far higher or lower than the one your doctor intended. A dose written in units on a syringe means nothing unless you know the concentration behind it.

Potency variation is the quieter cousin of that problem. The same label can correspond to different amounts of active ingredient from one batch to the next. You may notice the effect changing without knowing why, and there's no easy way to check potency at home.

Contamination and sterility are a third concern. Injectable products must be prepared under sterile conditions. When preparation falls short, the risks include infection at the injection site or, more rarely, in the bloodstream. You can't judge sterility by looking at a vial.

Stronger or unexpected side effects follow when the real dose is higher than the labeled one. The registered label lists nausea, vomiting, diarrhea, pancreatitis, and low blood sugar, which is more likely when semaglutide is combined with insulin or a sulfonylurea. Severe vomiting or diarrhea can also lead to dehydration. A higher-than-intended dose makes each of these more likely, so an unexplained change in how you feel deserves a call to your doctor.

If you notice something unusual, report it. ANVISA's pharmacovigilance system, NOTIVISA, accepts reports from patients and health professionals. Reports help regulators spot patterns, even when you're not sure the medicine caused the problem.

What to ask your doctor and pharmacy before choosing a compounded option

Start with your doctor. Ask why the registered product isn't the first option for you, and which clinical criteria would justify a compounded version. A good answer names a specific reason, such as an allergy to an ingredient, a dose the registered pen can't deliver, or a documented intolerance. If the only reason given is cost, keep asking. OzemBlog can help you prepare these questions, but your prescriber has the final say on your treatment.

Then ask the pharmacy three things: which API they use, which supplier it comes from, and whether they have a certificate of analysis for purity and concentration for each batch. A pharmacy that can't answer these questions clearly gives you a good reason to look elsewhere. Our guide at OzemBlog explains how to read a compounded label, which helps before you sit down with either professional.

Check the prescription itself. It should state the concentration in milligrams and the exact volume of each dose, with no room for guessing. Vague wording invites mistakes. Keep a copy of the prescription and the label, so you can compare them later. The OzemBlog team recommends bringing both to every appointment, since your doctor can then check the concentration against the registered label.

Some symptoms need prompt medical attention rather than a wait-and-see approach. Call your doctor or seek emergency care right away if you have:

vomiting that won't stop or keeps you from drinking fluids
severe abdominal pain, especially pain that spreads to your back
dizziness or fainting

Watch for dehydration too. Very dark urine, a very dry mouth, or confusion are signs your body is losing more fluid than it can replace. Don't adjust the dose on your own, even if it seems wrong. Stop and contact your prescriber. Changing the amount yourself is how a small measuring mistake becomes a bigger problem.

Bottom line: deciding with good information

Compounded semaglutide isn't the same product as the registered pen. Its weakest point is consistency: concentration, purity, and volume can differ between batches and between pharmacies. That doesn't make every compounded option unsafe, but it puts more of the checking on you and your care team.

Semaglutide can help with weight control or blood sugar control when it's part of medical follow-up. It isn't a cure, and no version of it should be presented as one. Your results depend on your health, your other medicines, and how closely the treatment is monitored.

Take the questions from the section above to your next appointment and write down the answers. A vague answer tells you something useful too. Then review ANVISA's current notices on medicines and GLP-1 products, and check the FDA's compounding page for the latest updates.

FAQ

Is compounded semaglutide safe?

It can be used in some situations, but it carries risks the registered product doesn't, mainly around dose accuracy, potency, and sterility. Safety depends on the pharmacy's quality controls and on your prescription being exact.

Is compounded semaglutide the same as the registered pen?

No. The registered product has an approved composition tested in clinical trials. A compounded version is prepared separately and isn't reviewed the same way, so its concentration and purity can vary.

Can I change my dose if the amount seems off?

No. Stop and contact your prescriber before changing anything. Dose decisions should be made by someone who can see your label and your health history.

Where do I report a side effect in Brazil?

You can report it to ANVISA through NOTIVISA, the national pharmacovigilance system. Your doctor or pharmacist can also file the report for you.

Sources

Why the shortage changed the conversation

What compounded semaglutide actually is